Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: An analysis from 5 Phase III studies

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 1, 2014, Pages 11-23

  Angiolillo, Dominick J ^a   Datto, Catherine ^b   Raines, Shane ^b   Yeomans, Neville D ^c,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

Low dose aspirin; Naproxen; Naproxen esomeprazole magnesium; NSAID; Safety profile; Tolerability

Indexed keywords

CELECOXIB; ESOMEPRAZOLE PLUS NAPROXEN; NAPROXEN; PLACEBO; ACETYLSALICYLIC ACID; ANTIULCER AGENT; DELAYED RELEASE FORMULATION; ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE PANCREATITIS; ADULT; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; APPENDIX PERFORATION; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; CEREBROVASCULAR DISEASE; COLITIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; COUGHING; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DUODENAL SCARRING; DUODENITIS; DUODENUM BLEEDING; DUODENUM DISEASE; DYSPEPSIA; EPIGASTRIC DISCOMFORT; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS HEMORRHAGE; ESOPHAGUS STENOSIS; ESOPHAGUS ULCER; ESOPHAGUS VARICES; FEMALE; GANGRENE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ATRIUM FLUTTER; HEART INFARCTION; HEMATEMESIS; HIP FRACTURE; HUMAN; HYPERCHLORHYDRIA; INCIDENCE; INCISIONAL HERNIA; LIMB FRACTURE; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; NAUSEA; NECROTIZING FASCIITIS; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RHEUMATOID ARTHRITIS; STAPHYLOCOCCUS INFECTION; STOMACH DISCOMFORT; STOMACH HEMORRHAGE; STOMACH MUCOSA LESION; SUICIDE ATTEMPT; SWELLING; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; GASTROINTESTINAL DISEASES; MULTICENTER STUDY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; ASPIRIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ESOMEPRAZOLE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS;

EID: 84902385838     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1035-4     Document Type: Article

References (39)

1. Laine L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120:594-606
2. Lanza FL, Chan FK, Quigley EMM (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728-738
3. Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284:1247-1255
4. Fries JF, Williams CA, Bloch DA, Michel BA (1991) Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 91:213-222
5. Solomon DH, Glynn RJ, Rothman KJ et al (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59:1097-1104
6. Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network metaanalysis. BMJ 342:c7086
7. Roth SH, Anderson S (2011) The NSAID dilemma: managing osteoarthritis in high-risk patients. Phys Sportsmed 39:62-74
8. Scheiman JM, Hindley CE (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32:667-677
9. Rostom A, Moayyedi P, Hunt R (2009) Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 29:481-496
10. Serrano P, Lanas A, Arroyo MT, Ferreira IJ (2002) Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16:1945-1953
11. Kim C, Beckles GL (2004) Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med 27:1-7 (Pubitemid 38813177)
12. Bhatt DL, Scheiman J, Abraham NS et al (2008) ACCF/ACG/ AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118:1894-1909
13. Chan FKL, Abraham NS, Scheiman JM, Laine L (2008) Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol 103:2908-2918
14. Desai SP, Solomon DH, Abramson SP et al (2008) Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 59:1058-1073
15. National Institute for Health and Clinical Excellence. Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59, 2008. http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf. Accessed 24 Jan 2013
16. Zhang W, Moskowitz RW, Nuki G et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartilage 16:137-162 (Pubitemid 351222155)
17. Yeomans N, Lanas A, Labenz J et al (2008) Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:2465-2473
18. Yeomans ND (2011) Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. Expert Rev Gastroenterol Hepatol 5:447-455
19. Lai KC, Lam SK, Chu KM et al (2002) Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346:2033-2038 (Pubitemid 34680594)
20. Abraham NS, El-Serag HB, Johnson ML et al (2005) National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129: 1171-1178 (Pubitemid 41446857)
21. Goldstein JL, Howard KB, Walton SM et al (2006) Impact of adherence to concomitant gastroprotective therapy on nonsteroi-dal- related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 4:1337-1345
22. Sturkenboom MCJM, Burke TA, Tangelder MJD et al (2003) Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 18:1137-1147 (Pubitemid 38021600)
23. Sturkenboom MCJM, Burke TA, Dieleman JP et al (2003) Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 42(Suppl 3):iii23-iii31 (Pubitemid 37407011)
24. van Soest EM, Sturkenboom MCJM, Dieleman JP et al (2007) Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 26:265-275 (Pubitemid 46985490)
25. Hochberg MC, Fort JG, Svensson O et al (2011) Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 27:1243-1253
26. Goldstein JL, Hochberg MC, Fort JG et al (2010) Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 32:401-413
27. Sostek MB, Fort JG, Estborn L, Vikman K (2011) Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 27:847-854
28. European Medicines Compendium UK. Vimovo™, 2012. www.medicines.org.uk/EMC/medicine/23883/SPC/VIMOVO+500+mg+20+mg+modified- release-tablets/. Accessed 7 June 2012
29. Food and Drug Administration (FDA). VIMOVO™ prescribing information, 2010. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022511lbl.pdf. Accessed 17 May 2012
30. Singh G, Fort JG, Goldstein JL et al (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119:255-266 (Pubitemid 43255067)
31. Lanas A, García-Rodríguez LA, Arroyo MT et al (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55:1731-1738 (Pubitemid 44893570)
32. Laine L, Smith R, Min K et al (2006) Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24:751-767
33. Goldstein JL, Lowry SC, Lanza FL et al (2006) The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2- selective inhibitor. Aliment Pharmacol Ther 23:1489-1498
34. Yeomans ND, Naesdal J (2008) Systematic review: ulcer definition in NSAID ulcer prevention trials. Aliment Pharmacol Ther 27:465-472 (Pubitemid 351300861)
35. Hawkey CJ, Wilson I, Naesdal J et al (2002) Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 51:344-350
36. Hawkey CJ, Karrasch JA, Szczepanski L et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734 (Pubitemid 28115091)
37. Scheiman JM, Behler EM, Loeffler KM, Elta GH (1994) Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 39:97-103 (Pubitemid 24041715)
38. Goldstein JL, Huang B, Amer F, Christopoulos NG (2004) Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post hoc subanalysis. Clin Ther 26:1637-1643 (Pubitemid 39643024)
39. Capone ML, Tacconelli S, Sciulli MG et al (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468-1471 (Pubitemid 38420172)